Anti-amyloid therapies lecanemab and donanemab receive nuanced clinical endorsement at AAN 2026. Stanford neurologist Christopher Lock, MD, offered a balanced AAN 2026 assessment of lecanemab (Leqembi, Eisai/Biogen) and donanemab (Kisunla, Eli Lilly), describing benefits as "marginal but still worth the try" while acknowledging that the field is entering a genuinely new era. The commentary reflects the pragmatic clinical consensus: statistically significant slowing of decline exists, but effect sizes remain modest in absolute terms. Near-term pipeline catalysts include Roche's trontinemab Phase 2 readout, which could reframe the amyloid-clearance debate if it demonstrates faster plaque removal with lower ARIA rates. The NICE reconsideration of lecanemab and donanemab — driven by the £20B+ per year unpaid carer cost argument — remains the pivotal access decision for ex-US markets.

Tavapadon NDA on track for July 2026 PDUFA — Parkinson's landscape watch intensifies. AbbVie's tavapadon, a first-in-class D1/D5 dopamine receptor partial agonist, filed its NDA on September 26, 2025 and carries a standard 10-month review PDUFA date of approximately July 2026. Phase 3 data demonstrated meaningful motor improvement with a potentially more selective receptor profile than existing D2/D3-dominant agonists such as pramipexole and ropinirole, with hypothetically lower impulse control disorder risk. An approval would hand AbbVie a meaningful Parkinson's anchor to complement its neuroscience portfolio. Competing pipeline assets include Bayer's bemdaneprocel (cell therapy) and Biogen/Denali's BIIB122 (LRRK2 inhibitor), both earlier stage. The Parkinson's commercial window is open for tavapadon.

Denali Therapeutics' BIIB122 / DNL151 LRRK2 program advances toward Phase 3 readouts in Parkinson's — with read-through implications for ALS pathway research. Denali Therapeutics' LRRK2 inhibitor BIIB122 (DNL151), partnered with Biogen, continues to advance through pivotal Phase 3 trials (LUMA in idiopathic Parkinson's; LIGHTHOUSE in LRRK2-mutation Parkinson's). The mechanism — inhibiting hyperactive LRRK2 kinase activity implicated in lysosomal dysfunction — has parallel relevance to ALS and other neurodegenerative pathways where lysosomal-autophagy disruption is increasingly viewed as a convergent mechanism. Phase 3 enrollment data and biomarker readouts in 2026 will be foundational signals for the broader kinase-inhibitor neurology pipeline.

Tolebrutinib CRL status creates durable commercial uncertainty for Sanofi's BTK inhibitor program — Roche's fenebrutinib remains on track for H1 2026 regulatory filing. Sanofi's tolebrutinib received a Complete Response Letter from the FDA in December 2025 for non-relapsing SPMS, and FDA discussions remain ongoing with no resubmission timeline confirmed. In the competitive vacuum, Roche's fenebrutinib — which posted Phase 3 positive results in both RMS (FENhance) and PPMS (FENtrepid) — is preparing a regulatory filing expected H1 2026. Novartis's remibrutinib rounds out a three-horse BTK race that will define the MS treatment architecture for the next decade. The tolebrutinib CRL, combined with the MS care access crisis (see below), creates payer leverage concerns that the entire BTK class must navigate carefully.

Neurocrine leverages tardive dyskinesia work-disruption data to sharpen early-diagnosis commercial narrative. Neurocrine Biosciences has published survey data documenting how tardive dyskinesia (TD) significantly impairs patients' and caregivers' ability to maintain employment — framing a health economics argument for earlier valbenazine (Ingrezza) initiation. The company's commercial strategy is evolving beyond efficacy claims toward a total burden-of-disease narrative, a tactic increasingly necessary as VMAT2 inhibitor prescribing faces generic competition pressure in adjacent movement disorder categories. With tavapadon's potential Parkinson's approval on the horizon, movement disorder neurology is set to become an intensely competitive prescribing battleground in the second half of 2026.

NeuroSense Therapeutics' PrimeC advances toward PARAGON Phase 3 following FDA clearance — ALS combination therapy thesis under active evaluation. NeuroSense Therapeutics' PrimeC, a fixed-dose combination of ciprofloxacin and celecoxib targeting ALS neuroinflammation and mitochondrial dysfunction, received FDA clearance for the PARAGON Phase 3 trial in November 2025. The program represents a differentiated multi-mechanism approach in a disease space where riluzole and AMX0035 (Relyvrio) have demonstrated only modest survival benefit. Phase 3 initiation and early enrollment data will be critical commercial and scientific signal points. The ALS combination therapy strategy also has implications for the broader neurodegeneration field, where single-target approaches have repeatedly underperformed.

Alzheimer's agitation market now has two approved agents — but Auvelity's safety profile creates a durable competitive wedge. With Axsome's Auvelity now approved alongside Otsuka/Lundbeck's Rexulti (brexpiprazole) for AD agitation, the market is formally a two-player approved space. However, the competitive dynamics strongly favor Auvelity in the medium term. Prescribers managing elderly AD patients have long sought a non-antipsychotic option to avoid the black-box elevated mortality warning on Rexulti, and Auvelity's NMDA/sigma-1 mechanism fills that gap precisely. Axsome's $8 billion peak sales projection is aggressive but not implausible given an addressable population where ~76% of AD patients exhibit agitation at some point in their disease course — representing millions of potential U.S. patients. Payer negotiations will be the critical execution test; expect Rexulti's established formulary positioning to create initial access friction for Auvelity.

AbbVie's 3-year atogepant dataset creates a durable evidence advantage over Pfizer's rimegepant in oral CGRP prevention. The oral CGRP preventive market — currently the fastest-growing segment in migraine — is increasingly being decided on long-term durability and tolerability data rather than acute efficacy alone. AbbVie's 3-year continuous safety and efficacy dataset for atogepant, presented at AAN 2026, is the first of its kind for any oral gepant in prevention. Pfizer's rimegepant holds approval for both acute and preventive episodic migraine treatment, giving it a dual-use convenience advantage, but lacks equivalent long-term preventive data. Meanwhile, the injectable CGRP mAb class (Teva's Ajovy, Amgen's Aimovig, AbbVie's Emgality, Lundbeck's Vyepti) remains dominant in high-frequency migraine, but oral agents are capturing the moderate-frequency episodic segment. AbbVie now has the data to defend formulary tier positioning aggressively against rimegepant on safety grounds alone.

MS care access crisis — nearly 50-day average neurology wait times — creates systemic commercial risk for all MS disease-modifying therapies. A new study presented at AAN 2026 finds that commercially insured U.S. patients wait nearly 50 days on average for a first neurology appointment, with MS patients waiting approximately 4 days longer than the general neurology population. Critically, the number of neurologists in a given region did not influence wait times, suggesting structural access barriers beyond simple physician supply. For MS drug manufacturers — particularly those launching complex BTK inhibitors requiring specialist initiation — this access bottleneck translates directly into delayed diagnosis, delayed treatment starts, and compressed commercial ramp trajectories. Roche, Sanofi, and Novartis should incorporate extended time-to-treat assumptions into their MS BTK launch models accordingly.

Comorbid autoimmune disease does not accelerate MS disability progression — data with underappreciated trial design implications. A large single-center study of 1,230 MS patients found that having a second non-neurological autoimmune condition does not accelerate disability milestone accrual compared to MS-only controls. While a patient-centered reassurance finding, the competitive landscape implications are notable: MS trials that have screened out patients with comorbid autoimmune diseases may have systematically excluded real-world patients without conferring a confounding disability signal. This could affect generalizability assumptions for BTK inhibitor trials (tolebrutinib, fenebrutinib, remibrutinib), most of which maintained strict autoimmune comorbidity exclusion criteria. Roche and Novartis may be able to leverage inclusive enrollment designs in future Phase 3 extensions without meaningful disability progression confounding.

NICE reconsideration of lecanemab and donanemab — anchored by £20B+ unpaid carer cost argument — sets pivotal ex-US access precedent for anti-amyloid class. Following an appeal that centered on unpaid carer costs exceeding £20 billion per year in the UK, NICE has ordered a reconsideration of both lecanemab (Leqembi) and donanemab (Kisunla). The outcome will carry outsized global significance: if NICE incorporates informal caregiver burden into the cost-effectiveness model, it could generate a template for other HTA bodies — including Germany's IQWiG and France's HAS — to expand how they measure AD treatment value. A positive NICE decision would materially improve Eisai and Eli Lilly's reimbursement trajectories in Europe and potentially pressure U.S. payers to revisit coverage restrictions based on comparable holistic burden arguments.

Tavapadon PDUFA (~July 2026) is the single most consequential near-term Parkinson's regulatory event. AbbVie's first-in-class D1/D5 partial agonist tavapadon faces its FDA decision in approximately July 2026, following the September 2025 NDA filing. An approval would inaugurate a new pharmacological class in Parkinson's disease — the first truly novel dopaminergic mechanism approved in decades. Watch for label negotiations around the impulse control disorder warning (potentially cleaner for D1/D5 vs. D2/D3), which will be a key commercial differentiator. Any advisory committee convened before PDUFA will signal FDA's risk calculus on the new mechanism class. Failure or a CRL would revert commercial momentum to levodopa-carbidopa intestinal gel (Duopa, AbbVie) and conventional oral agonists for the near term.

Roche's fenebrutinib regulatory filing (expected H1 2026) will crystallize the BTK inhibitor competitive field and force Sanofi's hand on tolebrutinib resubmission timing. With fenebrutinib Phase 3 positive data in both RMS and PPMS and a regulatory filing anticipated in the first half of 2026, Roche is poised to potentially reach market ahead of Sanofi's tolebrutinib (which holds a December 2025 CRL with no confirmed resubmission timeline) and Novartis's remibrutinib. The BTK class timing race now heavily favors Roche. The PDUFA date for fenebrutinib, once accepted, will be the benchmark against which Sanofi must accelerate its FDA dialogue. A two-year first-mover advantage for fenebrutinib in PPMS — an indication with virtually no approved disease-modifying options — would be commercially transformative for Roche's neuroscience franchise.

AD/PD 2026 (Copenhagen, March 17–21) datasets will circulate in follow-on publications through Q2–Q3 2026 — watch for trontinemab ARIA and clearance rate data. The AD/PD 2026 conference in Copenhagen, Denmark produced a series of anti-amyloid and biomarker presentations that are now entering the publication pipeline. The most commercially significant outstanding dataset is Roche's trontinemab Phase 2 update, which will clarify whether the recycling antibody mechanism achieves faster amyloid plaque clearance with lower ARIA rates than lecanemab or donanemab. Lower ARIA incidence would be the single most impactful differentiator for trontinemab's commercial positioning, given that ARIA monitoring burden is a primary prescriber friction point for the approved agents. Publication of full Phase 2 data in a peer-reviewed journal is anticipated by mid-2026.

Vinay Prasad's CBER departure (end of April 2026) introduces regulatory unpredictability for cell and gene therapy NDAs through mid-2026. With Vinay Prasad departing FDA CBER at the end of April 2026 and no replacement identified, gene therapy developers — including Latus Bio (HD program), NeuroSense (PrimeC/PARAGON), and Korsana (KRSA-028, data expected 2027) — face an interim period of institutional uncertainty within the regulatory office that oversees biological license applications. Companies with near-term BLA or IND submissions should anticipate potential review timeline extensions and proactively request pre-submission meetings to establish clear regulatory pathways before permanent CBER leadership is installed. The leadership transition is particularly consequential for novel CNS gene therapy platforms navigating the high-dose vs. low-dose vector safety discourse currently underway.

Auvelity's commercial launch in AD agitation will serve as a real-world test of payer willingness to reimburse branded non-antipsychotic behavioral neurology agents at scale. Axsome's $8 billion peak sales ambition for Auvelity in AD agitation rests critically on formulary access in a therapeutic area where antipsychotics — despite their mortality warnings — are cheap and deeply entrenched. The company's go-to-market strategy will need to navigate Medicare Part D formulary placement, prior authorization requirements, and step-edit policies requiring antipsychotic failure before access. Watch Q2 and Q3 2026 prescribing data for Auvelity's AD agitation ramp velocity relative to the MDD launch curve as a proxy for payer friction. A slow initial ramp driven by prior authorization burden would be the key downside signal; rapid penetration into the memory care and long-term care facility channel would validate the $8 billion projection's underlying assumptions.